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Abstract
Background: Non-healing ulcers are a major health problem worldwide and have great impact at personal, professional
and social levels, with high cost in terms of human and material resources. Recalcitrant non-healing ulcers are inevitable
and detrimental to the lower limb and are a major cause of non-traumatic lower limb amputations. Application of
autologous Platelet Rich Plasma (PRP) has been a major breakthrough for the treatment of non-healing and diabetic foot
ulcers, as it is an easy and cost-effective method, and provides the necessary growth factors that enhance tissue healing.
PRP is a conglomeration of thrombocytes, cytokines and various growth factors which are secreted by α-granules of
platelets that augment the rate of natural healing process with decrease in time. The purpose of this case series was to
evaluate the safety and efficacy of autologous platelet rich plasma for the treatment of chronic non-healing ulcers on the
lower extremity.
Methods: Autologous PRP was prepared from whole blood utilizing a rapid, intraoperative point-of-care system that
works on the principle of density gradient centrifugation. Twenty Four (24) patients with non-healing ulcers of different
etiologies, who met the inclusion criteria, were treated with single dose of subcutaneous PRP injections along with
topical application of PRP gel under compassionate use.
Results: The mean age of the treated patients was 62.5 ± 13.53 years and they were followed-up for a period
of 24 weeks. All the patients showed signs of wound healing with reduction in wound size, and the mean
time duration to ulcer healing was 8.2 weeks. Also, an average five fold increase in the platelet concentrate
was observed in the final PRP product obtained using the rapid point-of-care device, and the average platelet
dose administered to the patients was 70.10 × 108.
Conclusion: This case series has demonstrated the potential safety and efficacy of autologous platelet rich plasma for
the treatment of chronic non-healing ulcers.
Trial registration: NCT03026855, Registered 4 January 2017 ‘Retrospectively’
Keywords: Autologous platelet rich plasma, Non-healing ulcers, Point-of-care, Cellular therapy, Cytokines, Growth factors
Background
Chronic ulcers or non-healing ulcers are defined as
spontaneous or traumatic lesions, typically in lower ex-
tremities that are unresponsive to initial therapy or that
persist despite appropriate care and do not proceed to-
wards healing in a defined time period with an
underlying etiology that may be related to systemic dis-
ease or local disorders [1, 2]. There are many types of
non-healing ulcers that may include venous, arterial, dia-
betic, pressure and traumatic ulcers. The normal wound
healing process is dynamic and complex having three
phases: inflammation, tissue formation and tissue re-
modeling. However, if the normal healing process is
interrupted, an ulcer can become chronic in nature due
to lack of growth factors and cytokines which delay the
healing process [3]. Lower extremity ulcers comprise a
substantial proportion of chronic ulcers, especially those
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attributed to venous disease, diabetes, or arterial disease
[2]. Chronic non-healing ulcer is a major health problem
and is estimated to affect approximately 2–6 million
people in the United States alone [2, 4], while its preva-
lence in the world ranges from 1.9 to 13.1% [5, 6]. The
incidence of chronic ulcers is expected to increase as the
population ages and due to increased risk factors for
atherosclerotic occlusion such as smoking, obesity and
diabetes. It is estimated that almost 10% of the popula-
tion would develop a chronic wound in the course of a
lifetime, with wound related mortality rate of 2.5% [6].
These types of ulcers not only affect the quality of life
and productivity of the patient but also become a sub-
stantial financial burden for the patient and the health-
care system [7].
“More than 85% of lower limb amputations are pre-
ceded by foot or ankle ulcers and diabetes is one of the
major causes of non-traumatic amputations across the
world” [8]. Approximately 15–25% of individuals with
diabetes develop a foot ulcer, of which an estimated 12%
require lower extremity amputation [2]. Individuals with
diabetic foot ulcers are susceptible to infection and the
healing process is complicated by diabetic neuropathy
leading to chronic non-healing ulcers. Majority of the
chronic lower extremity ulcers are accounted by venous
disease as venous hypertension results in damage to ves-
sel walls and ultimately lead to skin breakdown [2]. The
prevalence of venous non-healing ulcers varies between
1 and 2% in the general population that accounts for al-
most 75–80% of all vascular ulcers [1, 9, 10].
The goal of ulcer treatment is to obtain wound closure
as expeditiously as possible. Conventional treatment for
non-healing ulcers includes wound cleansing, necrotic
tissue debridement, prevention, diagnosis, and, if neces-
sary, treatment of infection, mechanical off-loading,
management of blood glucose levels and local ulcer care
with dressing application [2, 11, 12]. However, there are
certain risk factors that commonly affect and contribute
to poor wound healing, these include: 1) Local causes,
such as presence of debris or necrotic tissue, infection in
the ulcer, tissue hypoxia, and repeated trauma; 2) Sys-
temic diseases, such as diabetes mellitus, immunodefi-
ciency, or malnutrition; and 3) Medications, such as
corticosteroids [3].
The standard available treatment modalities for non-
healing ulcers address these issues and provide optimal
local ulcer therapy with debridement of necrotic tissue
and provision of a moist wound healing environment,
pressure relief in the wound area, infection management
using antibiotics, antiseptics and topical antibacterial
agents, ischemia management, and medical management
of comorbidities. A wide variety of advanced treatment
for non-healing ulcer include hyperbaric oxygen therapy,
skin grafting, VAC (vacuum assisted closure) and
surgical management like angioplasty and reconstructive
surgery as needed [3, 13, 14].
Despite treatment, many chronic ulcers fail to heal or
persist for months/years and/or recur after healing, re-
quiring additional advanced wound care therapies for
adequate healing [3]. Cellular therapy for the treatment
of non-healing ulcer has been a major breakthrough in
the arena of vascular therapies. The use of patient’s own
body cells for wound/ulcer treatment relies upon the
components present in the blood and platelet concen-
trate, which contains various cytokines and growth
factors. These modular treatment options are safe and
effective and have no side effects. Over the last two de-
cades, emerging cellular therapies such as platelet-rich
plasma (PRP) therapy has gathered considerable atten-
tion for its potential use in the field of regenerative
medicine as a therapeutic agent in a range of chronic
conditions and can have an adjunctive role in a stan-
dardized, quality treatment plan [13, 15]. Autologous
PRP is a platelet suspension in plasma derived from
whole blood that is increasingly being used in clinical
practice for the treatment of chronic ulcers. The concen-
tration of platelets in PRP is 2–6 folds higher than that
of whole blood [1, 16]. The curative properties of PRP
rely on the fact that platelets are a physiological reser-
voir of a variety of growth factors, with healing function
which have an active role in tissue regeneration [15].
PRP is increasingly being used as a new alternative
approach in various fields of medicine (i.e. dentistry, trau-
matology, cosmetic surgery, ophthalmology, and dermatol-
ogy). Platelets contain proteins, known as growth factors
that trigger biological effects including directed cell migra-
tion (i.e. chemotaxis), angiogenesis, cell proliferation and
differentiation, which are key elements in the process of tis-
sue repair and regeneration. Several studies have also been
published on the role of platelet rich plasma for the treat-
ment of non-healing ulcers with positive response [17].
PRP is most often mixed with thrombin before appli-
cation in order to generate a fibrin gel, and a platelet-
growth-factors-rich exudate [18]. Thrombin activated
platelets release numerous growth factors from their α
-granules [19] that can modulate cell proliferation and dif-
ferentiation and accelerate soft tissue repair in vivo [20].
A recent meta-analysis of the use of PRP therapy in
cutaneous wounds showed that compared to control
wound care, PRP facilitated wound healing and the ul-
cers improved significantly in small hard-to-heal acute
and chronic wounds [21, 22]. In addition, platelets exert
antimicrobial activity against some bacteria of the skin,
and clinical data shows that the presence of infection is
reduced in PRP-treated wounds [22]. Therefore, PRP
therapy has several advantages that can provide a
practical and effective treatment approach for small
hard-to-heal ulcers [23].
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Autologous Platelet Rich Plasma treatment for Non-
healing ulcers has been a breakthrough in the stimula-
tion and acceleration of soft-tissue healing. PRP therapy
helps create a biological environment internally that is
most conducive for restoration of tissue homeostasis by
providing numerous signalling cytokines and growth fac-
tors that are important in tissue repair by diverse mech-
anisms including the regulation of inflammation,
angiogenesis, and synthesis and remodelling of new tis-
sue [15]. The advantages and merits of PRP are apparent
since it is easy, cost-effective and much more lasting
compared to other standard treatments and being au-
tologous in nature, it is free from communicable patho-
gens, making it a safe treatment modality with good
clinical results [10, 21].
The purpose of the present case series was to evaluate
the safety and efficacy of autologous PRP in treating non-
healing ulcer on lower extremity using a rapid, intra-
operative point-of-care technology at the patients’ bed side.
Methods
Patient selection criteria
In this case series 24 patients between the age group
18–85 years, with chronic or non-healing ulcers of vari-
ous aetiologies (such as pressure ulcers, venous ulcers,
arterial ulcers or diabetic foot ulcers) who were treated
with autologous PRP under compassionate use were in-
cluded. Patients with an ulcer of at least 4-weeks’ dur-
ation were eligible if they met additional inclusion/
exclusion criteria: Index foot ulcer located on the plan-
tar, medial, or lateral aspect of the foot (including all toe
surfaces); and wound area (length x width) measurement
between 0.5 and 10 cm2, inclusive. The index ulcers had
to be clinically non-infected (infection was diagnosed
through clinical signs and symptoms rather than culture
results) and full-thickness without exposure of bone,
muscle, ligaments, or tendons. Smokers and individuals
with systemic disease or history of anticoagulant, im-
munosuppressive, or antibiotic therapy in the last
3 months were excluded. Additionally, pregnant women,
patients with severe cardiovascular disorder and patients
with a bleeding disorder and uncontrolled sugar levels
were excluded. Patient history, physical examination,
and data of routine investigations were obtained.
Those patients who met the inclusion criteria were ex-
plained the entire treatment and follow-up procedure by
the study investigator, and only after obtaining voluntary
informed consent from the patients for the treatment
procedure, they were treated with PRP and their follow-
up data collected. The procedure was conducted in
accordance to the Declaration of Helsinki, and all care
was taken to maintain patient safety and confidentiality.
The study was approved by ‘The Independent Ethics
Committee (TIEC)’ (TIEC20123919) of the participating
institution and registered with clinicaltrials.gov (Identifier:
NCT03026855). All the included patients received single
dose of autologous PRP injections that was processed
using a 510(k) approved device and PRP gel application
over the wound/ulcer on the day of treatment procedure.
Preparation of Platelet Rich Plasma (PRP)
PRP was prepared using an advanced rapid point-of-care
technology, the Res-Q™ 60 PRP system (Thermogenesis
Corp., USA) at the patient’s bed side. This point-of-care
system is an automated, closed, sterile system that pro-
cesses and concentrates whole blood by density gradient
centrifugation in less than 15 min. The treatment pro-
cedure is non-invasive using minimally manipulated
autologous platelet concentrate, thereby decreasing the
chances of infection and cross contamination while pro-
cessing and administration of the cellular therapy.
Briefly, depending upon the size of ulcer or wound, and
under aseptic conditions, 40 to 60 ml of peripheral
blood was drawn in syringes containing anticoagulant
(Acid Citrate Dextrose – ACD-A) in the ratio of 3:17
(anticoagulant: whole blood) from patient’s anti-cubital
vein using a 21-gauge needle. Blood and anticoagulant
were thoroughly mixed before transferring to the pro-
cessing device, to prevent formation of blood clots,
which in turn facilitates higher cell recovery. At this
time, 1 mL aliquot of pooled blood was segregated and
later analyzed for pre-processed platelet counts and steril-
ity. The aspirated whole blood was then processed using
the Res-Q™ 60 PRP processing device at the patient’s bed-
side. The device works by separating peripheral blood into
three distinct layers; Erythrocytes settle at the substratum,
above that the plasma layer containing rich concentrate of
platelets (PRP) and platelet poor plasma (PPP) as the top
layer. After centrifugation, 7 mL of PRP was harvested
from the processing device using aseptic technique, of
which 1 mL aliquot was separated for post-processed
platelet counts and sterility analysis. The remaining 6 mL
was transferred to the sterile field for subcutaneous injec-
tions and activation of platelets for gel formation.
Preparation of activator solution
Activator solution was prepared by combining human
thrombin (500 IU/ml) (Baxter AG, Austria) with 1% Cal-
cium Chloride (CaCl2) in the ratio of 1:9, respectively.
The combination of Thrombin and Calcium Chloride
activates platelets in just fraction of seconds resulting in
fibrin matrix formation. Depending upon the wound
area, 2-3 mL of activator solution was prepared in the
sterile field and kept aside for application along with
PRP. Calcium chloride nullifies the effect of the acid
citrate anticoagulant used, and thrombin helps in acti-
vating fibrinogen, which is converted to fibrin and
cross-linked [24].
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Treatment procedure
The non-healing ulcers were first debrided to remove
any necrotic and infected tissues and the wound area
was cleaned thoroughly with betadine solution. Based on
the wound size and area, 2–3 mL of PRP was aliquoted
from the 6 mL prepared PRP solution for gel formation,
while the remaining 3–4 mL was injected subcutane-
ously inside and around the periphery of the wound/
ulcer. Autologous platelet gel was obtained by spraying
simultaneously equal volumes of PRP and activator solu-
tion (thrombin with calcium chloride) using a ratio ap-
plicator duploject system (dual port injection syringe
that permits the simultaneous injection of PRP and acti-
vator solution), topically over the ulcer or wound.
Within 5 to 10 s, a platelet gel was formed on the
wound, following which a non-absorbent dressing was
used to cover the wound/ulcer area (non-absorbent ster-
ile transparent sheet, Tegaderm™, 3 M Medical Inc.).
The dressing was changed on day 3 post-treatment; the
wound was irrigated with normal saline and assessed for
the presence of any form of infection. Following which
the dressing was frequently changed once a week and
the patients were followed up for a period of 24 weeks
post-treatment. Care and management efforts provided
at each treatment visit included cleansing and assessing
the wound and obtaining vital signs and an interim
wound history, including information regarding adverse
events, concomitant medications, nutrition and weight-
bearing status, and other aspects of care since the last
visit. Wounds were photographed before treatment and at
each follow-up visit after treatment using a digital camera.
Endpoints
Our primary objective was to assess the efficacy of PRP
in wound/ulcer healing by evaluating the percentage re-
duction in wound/ulcer size over the 24 weeks follow-up
period by visual inspection. The secondary objectives in-
cluded safety and feasibility of autologous PRP injec-
tions, time to wound/ulcer healing, improvement in pain
or discomfort, and quality of life.
Results
Twenty-four patients, each having one wound/ulcer of
varying etiology were included and treated with single
dose of PRP injections around the wound periphery and
topical administration of autologous platelet gel. Among
the included patients, 16 (66.6%) were males and 8
(33.33%) were females with a mean age of 62.5 ±
13.53 years. Out of 24 patients, 16 (66.6%) were in 61–
80 years age group, 7 (29.17%) were in 41–60 years age
group, and only 1 (4.17%) patient was <40 years. Add-
itionally, among the ulcers treated, there were 10
(41.67%) venous ulcers, 9 (37.5%) diabetic ulcers, 3
(12.5%) arterial ulcers and 2 (8.33%) pressure ulcers. The
duration of the non-healing ulcers presented by the
patients’ pre-treatment ranged from 9 to 24 weeks with
a mean duration of 16 weeks (Table 1). Wound/ulcer
healing was observed as early as 4 weeks post-PRP treat-
ment and the mean healing time was found to be almost
8.2 weeks ± 1.9 (Fig. 1). Four weeks after the application
of PRP gel, small islands of granulating tissue appeared
over the wound, and a significant reduction in wound
size and increase in tissue mass was observed as a sign
of healing and improvement.
All the patients showed healing of the wound/ulcer
where more than 90% reduction in wound size was ob-
served in 17 (70.83%) patients, followed by 80–90% re-
duction in wound size in 3 (12.5%) patients over the
24 weeks follow-up post-PRP application (Table 2).
Overall, significant reduction in wound size was ob-
served in all the treated patients.
PRP processing and administration was accomplished
at the patient’s bedside in a single sitting within 30 min
using the Res-Q™ 60 PRP system. Patients tolerated the
procedure well, and there was no bleeding, infection, or
procedure related complication, including local injection
site swelling in all the subjects on the day of treatment
after PRP injection and autologous PRP gel application.
The mean (±Standard Deviation) platelet counts in-
creased from 261.91 × 103 (±125.31)/μL to 1177.35 ×
103 (±787.95)/μL in the post-processed sample (Fig. 2).
Almost five fold increase in the platelet counts were ob-
served in the final PRP product, which was statistically
significant (p < 0.05). Furthermore, there was a statisti-
cally significant (p < 0.05) reduction in the Red Blood
Cell (RBC) counts in the post processed sample as com-
pared to whole blood, where the counts reduced by al-
most 80% and the mean RBC content in the final PRP
product was 0.65 × 106 (±0.34)/μL (Fig. 3). The mean
White Blood Cell (WBC) Count of all the patients
was 15.6 × 103 (±5.93)/μL in the concentrated PRP,
which was considerably higher than the mean WBC
count in whole blood (7.94 × 103 (±3.04)/μL) (Fig. 4),
and the mean platelet dose administered to the pa-
tient’s was 70.10 × 108.
Figure 5 shows the patient follow-up pictures, pre-
and post- PRP treatment, which clearly depicts the re-
duction in wound/ulcer size with time following PRP ad-
ministration. Reduction in pain and serous discharge
Table 1 Duration the wound/ulcers persisted before PRP
treatment





Suthar et al. Journal of Biomedical Science  (2017) 24:16 Page 4 of 10
from wounds was noted within 1 week post-treatment
and this could be due to the anti-inflammatory property
of PRP, which contains leukocytes. Also, no adverse ef-
fects were reported on the day of treatment and during
the patient’s follow-up period, deeming this as a safe and
effective treatment method for chronic non-healing ulcers.
Furthermore, the overall quality of life of the treated
patients improved tremendously post- PRP therapy.
Discussion
Leg ulcers are classified as acute or chronic according to
the duration they have persisted; However, there is no
specific length of time to define chronicity [7]. Chronic
wounds/ulcers come with significant cost and morbidity
for the patients and society as a whole. These non-
healing ulcers of lower extremity develop as a result of
peripheral neuropathy, ischemia, or trauma [25] and are
often difficult to treat. The main goal of any treatment
modality is to obtain wound closure expeditiously. The
conventional treatment includes adequate debridement,
control of infection, re-vascularization of ischemic tissue,
and avoidance of undue pressure on the wound. Skin
grafting has shown some efficacy, however they are not
capable of providing the necessary growth factors to
modulate the healing process and are expensive [10, 23].
In 1986, Knighton et al. showed that the use of autolo-
gous platelet factors accelerated epithelialization of
granulation tissue leading to complete repair of chronic
non-healing ulcers. This was the first clinical study that
demonstrated the promising role of locally acting factors
derived from autologous blood in promoting healing of
chronic cutaneous ulcers [26]. Platelets contain a large
number of growth factors and cytokines that play key
roles in inflammation and tissue repair, by contributing
towards haemostasis at sites of vascular injury. These
characteristics of platelets have led to the idea of using
platelet rich plasma as a therapeutic tool to promote
wound healing, particularly in patients whose tissue re-
pair is significantly impaired or delayed [27, 28].
PRP is a rich concentrate of platelets, cytokines and
growth factors dispersed in a very small amount of
plasma which can be prepared from a sample of centri-
fuged autologous blood. The α-granules of platelet rich
plasma contain various growth factors primarily Platelet
Derived Growth Factor (PDGF), Vascular Endothelial
Growth Factor (VEGF), Transforming Growth Factor-β
(TGF-β), Insulin-like Growth Factor (IGF) and Fibro-
blast Growth Factor (FGF) to name a few that locally at-
tract progenitor cells to stimulate proliferative and
differentiation activities and improve wound healing via
autocrine and paracrine mechanisms [16, 27, 28]. Plate-
lets initiate the wound healing process through release
of locally active growth factors [21, 29–31] that attract
undifferentiated cells to the site of injury and promote
their cell division. PRP may also limit inflammation by
Fig. 1 Distribution of cumulative ulcer healing time following PRP treatment
Table 2 Percentage Improvement in Wound/Ulcer Healing after
PRP treatment
Reduction in ulcer size
at the end of follow-up





> 90% 17 70.83
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Fig. 2 Distribution of Platelet counts at pre- and post- processing (*p < 0.05)
Fig. 3 Distribution of Reduction in RBC content in Pre- and Post-processed PRP (*p < 0.05)
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suppressing cytokine release at the site of injury, and
further improve the regeneration process by promoting
capillary angiogenesis and re-epithelialization because of
the presence of large amount of leukocytes [10, 32]. Our
results also reported the presence of 15.6 × 103 (±5.93)/
μL mean leukocytes in the PRP concentrate which was
almost two fold higher than the leukocyte count in the
pre-processed whole blood sample. Growth factors from
platelets are released only upon activation, wherein ap-
proximately 70% of the stored growth factors in the plate-
let are released within the first 10 min. Complete release
of platelet growth factors is accomplished within 1 h of ac-
tivation [16]. Therefore, it is recommended to activate
platelets just before applying PRP on to the ulcer area.
The growth factors released from PRP are important
in modulating mesenchymal cell recruitment, proliferation
and extracellular matrix synthesis during the healing
process [33]. PDGF stimulates chemotaxis, proliferation
and new gene expression in monocytes, macrophages and
fibroblasts in vitro, and these cell types are considered es-
sential for tissue repair. Transforming growth factor-β
stimulates cell proliferation, protein synthesis and collagen
synthesis. It also inhibits growth of many epithelial
tumour cells and fibroblastic cell lines. Platelet derived
angiogenesis factor is a polypeptide capable of stimulating
new capillary growth by inducing migration of endothelial
cells. Platelet derived epithelial cell growth factor is
partially responsible for the initial influx of neutrophils
into the wound space; it is also a mitogen for many cells,
including epithelial cells and fibroblasts. More recently, it
was suggested that this was the mechanism by which
platelet factors influence the process of angiogenesis
and revascularisation, thus promoting granulation tis-
sue formation [7]. In addition to growth factors, leu-
cocytes also help in wound healing as they help in
preventing infections.
Activated platelets, apart from growth factors, also re-
lease large amounts of elements that contribute to pri-
mary homeostasis, like fibrinogen, serotonin, fibronectin,
factor V, factor VIII (Von Willebrand factor) and
calcium (factor IV). These result in formation of platelet
aggregates (clots), causing platelet stabilization by cross-
linked fibrin and sticky glycoproteins. The formed fibrin
matrix promotes cell permeation with monocytes, fibro-
blasts and other progenitor cells that play an important
role in ulcer healing [16]. A major advantage of PRP over
the use of single recombinant human Growth Factor
delivery is the release of multiple growth factors and dif-
ferentiation of factors upon platelet activation [10, 34].
In our case series, 24 patients with one wound/ulcer
per patient were treated with a single dose of a combin-
ation of autologous PRP gel and subcutaneous injections
of PRP in and around the wound periphery. All the pa-
tients showed healing of the wound with reduction in
Fig. 4 Distribution of WBC counts in pre- and post- processed PRP
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wound size, and the mean time to healing of the ulcers
was 8.2 ± 1.9 weeks. Reduction in pain was observed in
all the patients post-treatment and also, the quality of
life of the patients significantly improved. The results
demonstrated the safety and efficacy of autologous PRP
in treating chronic non-healing ulcers. PRP was prepared
using a rapid point-of-care device, the Res-Q™ 60 PRP
system, an autologous platelet separator instrument
designed to be used at the patient’s bedside for the safe
and rapid preparation of platelet rich plasma from periph-
eral blood. The device concentrated platelets three to five
(3–5) fold higher as compared to baseline values in whole
peripheral blood with minimal manipulation. Additionally,
the point-of-care approach avoids the need for a second
procedure (at a different time point) to harvest and im-
plant cells making it more cost-effective (≈USD280 per
procedure) and this type of therapy also circumvents many
of the limitations of exogenous cell therapy by avoiding in
vitro cell manipulation, costly cell expansion, and the need
for Good Manufacturing Practice (GMP) facility.
A study conducted by Frykberg et al., on 49 patients
with 65 non-healing ulcers showed that 63 of 65 ulcers
responded with a reduction in area, volume and under-
mining of the ulcers in a mean duration of 2.8 weeks
with 3.2 treatments [35]. Another study by Kakudo et
al., treated five cases of intractable skin ulcer with
autologous PRP, among which three ulcers healed com-
pletely within 4 weeks and epithelialiazation of wound
occurred within 6.6 weeks on average [28]. A prospect-
ive, randomized, controlled, blinded multicenter study
conducted by Driver et al., initially included 72 patients
with diabetic foot ulcers who were treated with autolo-
gous platelet-rich plasma gel or control (saline gel).
However, 32 patients were excluded from the final
protocol because of protocol violations and failure to
complete treatment. Their study results showed that sig-
nificantly more wounds healed in patients treated with
platelet-rich plasma gel (13 out of 16 or 81.3%) than
patients treated with control gel (eight out of 19 or
42.1%). However, the study had several limitations in-
cluding small sample size, protocol violations occurring
during the study period, and high rate of patient drop-
outs [13]. Furthermore, Steenvoorde et al., conducted a
study on 12 patients with 13 wounds, showing that
seven of 13 wounds required more than one application,
with a mean number of 2.2 applications and a mean
treatment period of 4.2 weeks [36]. The results from our
case series were concurrent with previously published
studies in terms of healing time, even though in our
study only a single dose of PRP was administered.
Several studies have been conducted on the use of
PRP for the treatment of non-healing ulcers and the
Fig. 5 Patient follow-up images depicting the treatment efficacy of PRP during follow-up period
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results have been promising, however, currently, there is a
paucity of critical scientific data regarding the beneficial
effects of PRP in clinical procedures. PRP is an autologous
preparation, making it a safe treatment modality as com-
pared to allogenic preparations and is free from concerns
over transmissible diseases [21, 37]. Moreover, PRP
requires no special considerations regarding antibody
formation, thereby, effectively preventing the risk of
graft vs. host disease and leading to better acceptance
by patients [21].
Conclusion
In conclusion, the results from our case series showed
that PRP is a safe and effective treatment modality for
chronic non-healing ulcers. Using PRP to treat chronic
wounds/ulcers may not only enhance healing, but also
prevent lower extremity amputations caused by non-
healing wounds. Therefore, further research and con-
trolled, randomized prospective clinical trials on larger
patient population are necessary to validate the results.
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